Regen BioPharma, Inc.
RGBP
$0.01
$0.0020.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.40K | 59.10K | 59.10K | 59.10K | 59.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.40K | 59.10K | 59.10K | 59.10K | 59.40K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 59.40K | 59.10K | 59.10K | 59.10K | 59.40K |
| SG&A Expenses | 170.70K | 99.80K | 172.40K | 120.40K | 111.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 182.40K | 99.80K | 172.40K | 120.40K | 144.80K |
| Operating Income | -123.10K | -40.80K | -113.30K | -61.40K | -85.40K |
| Income Before Tax | -572.50K | -167.30K | -19.40K | -515.40K | -270.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -572.50K | -167.30K | -19.40K | -515.40K | -270.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -572.50K | -167.30K | -19.40K | -515.40K | -270.70K |
| EBIT | -123.10K | -40.80K | -113.30K | -61.40K | -85.40K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.01 | 0.00 | -0.13 | -0.06 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | -0.08 | -0.04 |
| EPS Diluted | -0.02 | -0.01 | 0.00 | -0.13 | -0.06 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | -0.08 | -0.04 |
| Average Basic Shares Outstanding | 33.02M | 23.75M | 21.55M | 4.11M | 4.52M |
| Average Diluted Shares Outstanding | 33.02M | 23.75M | 21.55M | 4.11M | 4.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |